ATA14996A - USE OF GALANTHAMINE FOR PRODUCING MEDICINAL PRODUCTS FOR TREATING TRISOMY 21 OR RELATED TRISOMY SYNDROME - Google Patents

USE OF GALANTHAMINE FOR PRODUCING MEDICINAL PRODUCTS FOR TREATING TRISOMY 21 OR RELATED TRISOMY SYNDROME

Info

Publication number
ATA14996A
ATA14996A AT0014996A AT14996A ATA14996A AT A14996 A ATA14996 A AT A14996A AT 0014996 A AT0014996 A AT 0014996A AT 14996 A AT14996 A AT 14996A AT A14996 A ATA14996 A AT A14996A
Authority
AT
Austria
Prior art keywords
trisomy
galanthamine
treating
medicinal products
syndrome
Prior art date
Application number
AT0014996A
Other languages
German (de)
Other versions
AT402691B (en
Original Assignee
Sanochemia Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanochemia Ltd filed Critical Sanochemia Ltd
Priority to AT0014996A priority Critical patent/AT402691B/en
Publication of ATA14996A publication Critical patent/ATA14996A/en
Priority to AU14328/97A priority patent/AU1432897A/en
Priority to PCT/AT1997/000011 priority patent/WO1997026887A1/en
Priority to EP97900892A priority patent/EP0876147A1/en
Application granted granted Critical
Publication of AT402691B publication Critical patent/AT402691B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT0014996A 1996-01-26 1996-01-26 USE OF GALANTHAMINE FOR PRODUCING MEDICINAL PRODUCTS FOR TREATING TRISOMY 21 OR RELATED TRISOMY SYNDROME AT402691B (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AT0014996A AT402691B (en) 1996-01-26 1996-01-26 USE OF GALANTHAMINE FOR PRODUCING MEDICINAL PRODUCTS FOR TREATING TRISOMY 21 OR RELATED TRISOMY SYNDROME
AU14328/97A AU1432897A (en) 1996-01-26 1997-01-27 Use of galanthamine in the preparation of novel drugs
PCT/AT1997/000011 WO1997026887A1 (en) 1996-01-26 1997-01-27 Use of galanthamine in the preparation of novel drugs
EP97900892A EP0876147A1 (en) 1996-01-26 1997-01-27 Use of galanthamine in the preparation of novel drugs

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AT0014996A AT402691B (en) 1996-01-26 1996-01-26 USE OF GALANTHAMINE FOR PRODUCING MEDICINAL PRODUCTS FOR TREATING TRISOMY 21 OR RELATED TRISOMY SYNDROME

Publications (2)

Publication Number Publication Date
ATA14996A true ATA14996A (en) 1996-12-15
AT402691B AT402691B (en) 1997-07-25

Family

ID=3482843

Family Applications (1)

Application Number Title Priority Date Filing Date
AT0014996A AT402691B (en) 1996-01-26 1996-01-26 USE OF GALANTHAMINE FOR PRODUCING MEDICINAL PRODUCTS FOR TREATING TRISOMY 21 OR RELATED TRISOMY SYNDROME

Country Status (4)

Country Link
EP (1) EP0876147A1 (en)
AT (1) AT402691B (en)
AU (1) AU1432897A (en)
WO (1) WO1997026887A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000032199A1 (en) * 1998-12-01 2000-06-08 Sanochemia Pharmazeutika Aktiengesellschaft Use of galanthamine and galanthamine derivatives in the case of acute functional brain damage
US20030162770A1 (en) * 2002-02-22 2003-08-28 Davis Bonnie M. Use of modulators of nicotinic receptors for treatment of cognitive dysfunction
US20100168081A1 (en) * 2005-08-11 2010-07-01 Adriana Di Polo Galantamine as a neuroprotective drug for retinal ganglion cells

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4663318A (en) * 1986-01-15 1987-05-05 Bonnie Davis Method of treating Alzheimer's disease
DE4010079A1 (en) * 1990-03-29 1991-10-02 Lohmann Therapie Syst Lts PHARMACEUTICAL FORMULATION FOR THE TREATMENT OF ALCOHOLISM
US5336675A (en) * 1991-05-14 1994-08-09 Ernir Snorrason Method of treating mania in humans
US5177070A (en) * 1991-11-15 1993-01-05 Ciba-Geigy Corporation Method of treating physiologic male erectile impotence
DE4301783C1 (en) * 1993-01-23 1994-02-03 Lohmann Therapie Syst Lts Transdermal system per admin. of galanthamine - esp. for treatment of Alzheimer's disease and alcohol addiction
DE4301782C1 (en) * 1993-01-23 1994-08-25 Lohmann Therapie Syst Lts Use of galanthamine to treat nicotine addiction
US5428159A (en) * 1994-04-08 1995-06-27 Ciba-Geigy Corporation Method of manufacture of (-)-galanthamine in high yield and purity substantially free of epigalanthamine
DE19509663A1 (en) * 1995-03-17 1996-09-19 Lohmann Therapie Syst Lts Process for the isolation of galanthamine

Also Published As

Publication number Publication date
WO1997026887A1 (en) 1997-07-31
AT402691B (en) 1997-07-25
EP0876147A1 (en) 1998-11-11
AU1432897A (en) 1997-08-20

Similar Documents

Publication Publication Date Title
DE69917625D1 (en) IMPLANTS FOR ADMINISTERING ACTIVE SUBSTANCES AND METHOD FOR PRODUCING IMPLANTS
DE69622074D1 (en) Cystine-silicone copolymers and their use for the treatment of keratinous materials
DE69332732D1 (en) Pharmaceutical composition and method for the treatment of hyperlipidemia and arteriosclerosis
ATE275383T1 (en) OXADIC ACIDS AND RELATED COMPOUNDS FOR THE TREATMENT OF SKIN DISORDERS
ATE260652T1 (en) MEDICINAL PRODUCTS AND METHODS FOR THE TREATMENT OF ATTENTION DISORDERS AND ATTENTION/HYPERACTIVITY DISORDERS USING METHYLPHENIDATE
DE3856398T2 (en) Process for the treatment of sliding bodies
DE69829625D1 (en) Process and apparatus for the treatment of perfluorocarbon
DE69212620D1 (en) Use of glycosaminoglycans for the treatment of diabetic nephropathy and diabetic neuropathy
DE69115921D1 (en) METHOD FOR THE TREATMENT AND USE OF WASTE
DE69427774T2 (en) CONTINUOUS PROCESS FOR THE TREATMENT OF FOODSTUFFS
DE69218621D1 (en) CONTINUOUS FORM AND DEVICE FOR THE PRODUCTION OF LETTERS thereof
DE4492763T1 (en) Process and apparatus for the production of laminated products
ATE269077T1 (en) USE OF TETRAHYDROPYRIDINE DERIVATIVES FOR THE PRODUCTION OF MEDICINAL PRODUCTS FOR THE TREATMENT OF DEMYELINIZING DISEASES
DE69011951D1 (en) Process for the treatment and production of material.
DE69734296D1 (en) NEW DIKAFFEOYLCHINIC ACID DERIVATIVES AND THEIR USE FOR THE TREATMENT OF HEPATITIS B
DE69620691T2 (en) Therapeutic agent for the treatment of hypercholesterolemia
DE69626311T2 (en) COMPOSITION FOR THE TREATMENT OF LAUNDRY AND METHOD THEREFOR
DE69621447D1 (en) USE OF NITROFLAVONOIDS FOR TREATING ANXIETIES
ATE222491T1 (en) MELATONIN DERIVATIVES FOR USE IN THE TREATMENT OF SLEEP DISORDERS
DE69607559D1 (en) Process for the treatment of phenol tar
DE69729735D1 (en) USE OF BENZOPYRANOLS FOR THE TREATMENT OF NEUROLOGICAL DISEASES
ATA901396A (en) USE OF MELATONIN FOR THE TREATMENT OF PATIENTS SUGGESTED IN DRUG ADDICTION
DE69701458D1 (en) USE OF BUCKMINSTERFULLEREN FOR TREATING NEUROTOXIC INJURIES
ATA14996A (en) USE OF GALANTHAMINE FOR PRODUCING MEDICINAL PRODUCTS FOR TREATING TRISOMY 21 OR RELATED TRISOMY SYNDROME
DE69418931D1 (en) Use of VIP and its analogs and fragments for the treatment of neurodegenerative diseases

Legal Events

Date Code Title Description
REN Ceased due to non-payment of the annual fee
ELJ Ceased due to non-payment of the annual fee
EWE Authorization for restitution
EIH Change in the person of patent owner
ELJ Ceased due to non-payment of the annual fee